Evidence map›Paper›PMID 37508427›Full record

ReviewBiology2023

Next-Generation Sequencing Technology: Current Trends and Advancements.

Heena Satam, Kandarp Joshi, Upasana Mangrolia, Sanober Waghoo, Gulnaz Zaidi, Shravani Rawool, Ritesh P Thakare, Shahid Banday, Alok K Mishra, Gautam Das and 1 more

Erratum issuedAbstract readReview
In one paragraph

Review in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 659 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
659citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

659 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Insights Into Spatial Transcriptomics: Exploring Recent Technical Developments and Their Diverse Applications.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

599 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Heena SatammiBiome Therapeutics, Mumbai 400102, India.
Kandarp JoshimiBiome Therapeutics, Mumbai 400102, India.ORCID 0000-0002-2153-0110
Upasana MangroliamiBiome Therapeutics, Mumbai 400102, India.ORCID 0000-0001-7670-0239
Sanober WaghoomiBiome Therapeutics, Mumbai 400102, India.
Gulnaz ZaidimiBiome Therapeutics, Mumbai 400102, India.ORCID 0009-0007-8149-0388
Shravani RawoolmiBiome Therapeutics, Mumbai 400102, India.
Ritesh P ThakareDepartment of Molecular Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-7426-2519
Shahid BandayDepartment of Molecular Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.
Alok K MishraDepartment of Molecular Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-7742-2426
Gautam DasmiBiome Therapeutics, Mumbai 400102, India.
Sunil K MaloniaDepartment of Molecular Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-2727-5165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of next-generation sequencing (NGS) has brought about a paradigm shift in genomics research, offering unparalleled capabilities for analyzing DNA and RNA molecules in a high-throughput and cost-effective manner. This transformative technology has swiftly propelled genomics advancements across diverse domains. NGS allows for the rapid sequencing of millions of DNA fragments simultaneously, providing comprehensive insights into genome structure, genetic variations, gene expression profiles, and epigenetic modifications. The versatility of NGS platforms has expanded the scope of genomics research, facilitating studies on rare genetic diseases, cancer genomics, microbiome analysis, infectious diseases, and population genetics. Moreover, NGS has enabled the development of targeted therapies, precision medicine approaches, and improved diagnostic methods. This review provides an insightful overview of the current trends and recent advancements in NGS technology, highlighting its potential impact on diverse areas of genomic research. Moreover, the review delves into the challenges encountered and future directions of NGS technology, including endeavors to enhance the accuracy and sensitivity of sequencing data, the development of novel algorithms for data analysis, and the pursuit of more efficient, scalable, and cost-effective solutions that lie ahead.

Indexed as

bioinformaticsgenomicsIlluminamicrobiomemolecular diagnosticsNanoporenext-generation sequencingPacBiopyrosequencing

Identifiers

PMID37508427
PMCPMC10376292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.